137 related articles for article (PubMed ID: 23289967)
1. Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: a rebuttal.
Hemker HC; Béguin S
J Thromb Haemost; 2013 Mar; 11(3):564. PubMed ID: 23289967
[No Abstract] [Full Text] [Related]
2. Low-molecular-weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: a reply to rebuttal.
Buyue Y; Misenheimer TM; Sheehan JP
J Thromb Haemost; 2013 Mar; 11(3):565-6. PubMed ID: 23332108
[No Abstract] [Full Text] [Related]
3. Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism.
Buyue Y; Misenheimer TM; Sheehan JP
J Thromb Haemost; 2012 Oct; 10(10):2086-98. PubMed ID: 22905983
[TBL] [Abstract][Full Text] [Related]
4. Interindividual variability of in vitro response to anticoagulants.
Samama MM
Thromb Res; 2011 Jan; 127(1):1. PubMed ID: 21075429
[No Abstract] [Full Text] [Related]
5. Inter-individual variability of effect of 7 low molecular weight antithrombin-dependent anticoagulants studied in vitro with calibrated automated thrombography.
Hacquard M; Perrin J; Lelievre N; Vigneron C; Lecompte T
Thromb Res; 2011 Jan; 127(1):29-34. PubMed ID: 20850172
[TBL] [Abstract][Full Text] [Related]
6. Challenges with heparin-based anticoagulation during cardiopulmonary bypass in children: Impact of low antithrombin activity.
Manlhiot C; Gruenwald CE; Holtby HM; Brandão LR; Chan AK; Van Arsdell GS; McCrindle BW
J Thorac Cardiovasc Surg; 2016 Feb; 151(2):444-50. PubMed ID: 26553458
[TBL] [Abstract][Full Text] [Related]
7. Antithrombin levels during pediatric cardiopulmonary bypass: Key to changing a decades-old paradigm for anticoagulation?
Andropoulos DB; Fraser CD
J Thorac Cardiovasc Surg; 2016 Feb; 151(2):305-6. PubMed ID: 26578182
[No Abstract] [Full Text] [Related]
8. Activation of blood coagulation at heparin-coated surfaces.
Blezer R; Fouache B; Willems GM; Lindhout T
J Biomed Mater Res; 1997 Oct; 37(1):108-13. PubMed ID: 9335355
[TBL] [Abstract][Full Text] [Related]
9. Mode of action of heparin and related drugs.
Hemker HC; Beguin S
Semin Thromb Hemost; 1991; 17 Suppl 1():29-34. PubMed ID: 1648791
[No Abstract] [Full Text] [Related]
10. Selective disruption of heparin and antithrombin-mediated regulation of human factor IX.
Westmark PR; Tanratana P; Sheehan JP
J Thromb Haemost; 2015 Jun; 13(6):1053-63. PubMed ID: 25851619
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of factor IXa inhibition by antithrombin in the presence of unfractionated and low molecular weight heparins and fucoidan.
Mauray S; de Raucourt E; Talbot JC; Dachary-Prigent J; Jozefowicz M; Fischer AM
Biochim Biophys Acta; 1998 Sep; 1387(1-2):184-94. PubMed ID: 9748565
[TBL] [Abstract][Full Text] [Related]
12. Antithrombin and heparin cofactor II-mediated inactivation of alpha-thrombin by a synthetic, sulfated mannogalactan.
Gracher AH; Cipriani TR; Carbonero ER; Gorin PA; Iacomini M
Thromb Res; 2010 Sep; 126(3):e180-7. PubMed ID: 20553946
[TBL] [Abstract][Full Text] [Related]
13. From unfractionated heparin to pentasaccharide: Paradigm of rigorous science growing in the understanding of the in vivo thrombin generation.
Spadarella G; Di Minno A; Donati MB; Mormile M; Ventre I; Di Minno G
Blood Rev; 2020 Jan; 39():100613. PubMed ID: 31471127
[TBL] [Abstract][Full Text] [Related]
14. Depolymerized holothurian glycosaminoglycan with novel anticoagulant actions: antithrombin III- and heparin cofactor II-independent inhibition of factor X activation by factor IXa-factor VIIIa complex and heparin cofactor II-dependent inhibition of thrombin.
Nagase H; Enjyoji K; Minamiguchi K; Kitazato KT; Kitazato K; Saito H; Kato H
Blood; 1995 Mar; 85(6):1527-34. PubMed ID: 7888673
[TBL] [Abstract][Full Text] [Related]
15. Blocking inhibition of prothrombinase by tissue factor pathway inhibitor alpha: a procoagulant property of heparins.
Wood JP; Baumann Kreuziger LM; Desai UR; Mast AE
Br J Haematol; 2016 Oct; 175(1):123-32. PubMed ID: 27301751
[TBL] [Abstract][Full Text] [Related]
16. Coagulation inhibition capacities of low-molecular mass and unfractionated heparin, as determined by thrombin generation.
Elgue G; Sanchez J; Egberg N; Olsson P
Thromb Res; 1994 Sep; 75(5):539-49. PubMed ID: 7992254
[TBL] [Abstract][Full Text] [Related]
17. Purification and partial characterization of draculin, the anticoagulant factor present in the saliva of vampire bats (Desmodus rotundus).
Apitz-Castro R; Béguin S; Tablante A; Bartoli F; Holt JC; Hemker HC
Thromb Haemost; 1995 Jan; 73(1):94-100. PubMed ID: 7740503
[TBL] [Abstract][Full Text] [Related]
18. In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry.
Tanaka KA; Szlam F; Rusconi CP; Levy JH
Thromb Haemost; 2009 May; 101(5):827-33. PubMed ID: 19404534
[TBL] [Abstract][Full Text] [Related]
19. Fucosylated chondroitin sulfate inhibits plasma thrombin generation via targeting of the factor IXa heparin-binding exosite.
Buyue Y; Sheehan JP
Blood; 2009 Oct; 114(14):3092-100. PubMed ID: 19414859
[TBL] [Abstract][Full Text] [Related]
20. Heparin coating of tantalum coronary stents reduces surface thrombin generation but not factor IXa generation.
Blezer R; Cahalan L; Cahalan PT; Lindhout T
Blood Coagul Fibrinolysis; 1998 Jul; 9(5):435-40. PubMed ID: 9712292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
